StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30473% above fair value
$95.05−0.06 (-0.06%)

Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –

Kiniksa Pharmaceuticals International pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Kiniksa Pharmaceuticals International's pe ratio was 98.7× on Nov 11, 2026, against 94.5× a year earlier. Over the last 3 years it ranged from 4.1× to 970.8×, with a median of 76.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202698.7×+7.1
2025Dec 31, 202591.7×−240.8
2024Jul 31, 2024332.5×+327.8
2023Oct 31, 20234.7×−2.8
2022Dec 30, 20227.5×–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?